The Faculty has today signed up to the 'AllTrials' campaign (www.alltrials.net), that has recently been established to champion transparency in clinical trial data.
The aims of the campaign are that "All trials past and present should be registered, and the full methods and the results reported". The Faculty has shown a longstanding commitment to the publication and dissemination of trial data through our Guiding Principles for Pharmaceutical Physicians, and we see the aims of the AllTrials campaign as being closely aligned to this commitment. The Guiding Principles unequivocally state that "All studies should be performed to increase knowledge in some useful way, and there should be openness and honesty in the sharing of this knowledge with the wider world. Study findings need to be communicated, whatever the outcome, for the benefit of the community at large". We believe that the increased scrutiny of clinical trial data will result in enhanced and more rigorous science, and will ultimately lead to better health outcomes for patients. The proposal to sign up to the campaign received unanimous support from the Faculty Board.
Pharmatimes has covered the Faculty's signing up to alltrials in an article here.
The Ethical Standards in Health and Life Sciences Group (ESHLSG) launch a Medical Education Survey. All Faculty members are invited to participate - please click here for details.
Professor Alan Boyd has been elected as the next Vice President of the Faculty of Pharmaceutical Medicine.
The Faculty of Pharmaceutical Medicine is pleased to announce that Professor Alan Boyd has been elected as its next Vice President. Professor Boyd will take up office on 29 November 2012 for a three-year term.
On learning the news of his election Professor Boyd said:
'I am honoured to have been elected as the next Vice-President of the Faculty. The next few years are going to be very important for the membership of the Faculty in relation to continued educational needs, support for revalidation and communicating about what we do as a Specialty to the wider medical community and patient organisations. I am looking forward to being involved in these matters and in supporting our next President, Dr Keith Bragman, and the Faculty in any way I can'.
The Faculty of Pharmaceutical Medicine is pleased to announce that Dr Keith Bragman has been elected as its next President. Dr Bragman will take up office on 29 November 2012 for a three-year term.
On learning the news of his election Dr Bragman said:
'I am delighted to have been elected as the next president of the Faculty. I hope to build upon the excellent work of Dr Richard Tiner and former presidents. The Faculty is now a more mature organisation and much has already been done to establish pharmaceutical medicine as an important speciality. We face the challenge of implementing revalidation, coping with major changes within the NHS, and the increased need to support pharmaceutical physicians both at home and abroad. In addition we must do more to reach out beyond our professional colleagues to the general public and patients. I look forward to taking on these new challenges and doing my best to represent the Faculty and its membership.'
Today sees the release of an important document designed to promote and clarify the relationships between the pharmaceutical industry and healthcare professionals. It contains a number of recommendations for open and positive ‘standards of engagement' and ways to encourage collaboration, for the benefit of patients and the public.
The ‘Guidance on Collaboration between Healthcare Professionals and the Pharmaceutical Industry' has been produced by the Ethical Standards in Health and Life Sciences group (ESHLSG) - formed of the Faculty, Academy of Medical Royal Colleges, Department of Health, ABPI, RCP, Scottish and Welsh Governments and a number of other prominent healthcare organisations.
Commenting on the document, Dr Richard Tiner, former President of the Faculty of Pharmaceutical Medicine (from November 2009 to November 2012), said:
"As the standard-setting body for doctors working in the pharmaceutical industry, and a link between these two communities, the Faculty of Pharmaceutical Medicine welcomes the release of this guidance document. We believe that the principles within it herald a new era of collaborative working that will encourage innovation in science and medical practice in the UK for the benefit of patients. The Faculty is particularly pleased that the issue of adverse event reporting, point 9, has been highlighted, as the utilisation of the yellow-card scheme by healthcare professionals and patients is vital in developing safe and effective medicines."